Guerbet to acquire Mallinckrodt's contrast media business in $270M deal
Guerbet has entered into a definitive agreement under which it will acquire Mallinckrodt's contrast media and delivery systems business (CMDS).
Mallinckrodt's CMDS business recorded sales of close to $210 million in the first six months of fiscal 2015. Guerbet is acquiring 100 percent of the CMDS business including the production sites, the intellectual property rights and the distribution subsidiaries in the various geographical areas, in a transaction valued at approximately $270 million. The pro forma combined sales of Guerbet and the CMDS business were close to €800 million ($884 million) in 2014 with a global workforce of around 2,500."This acquisition transforms and accelerates Guerbet's future: it doubles our turnover, enables us to extend our geographical footprint and creates complementarities in both contrast media and imaging solutions and services," said Yves L'Epine, Guerbet's CEO, in a statement. "We will be very pleased to welcome Mallinckrodt's CMDS colleagues to successfully and rapidly complete this integration together after the closing and create a new global leader in medical imaging".
Guerbet will gain four production sites in Ireland and North America and a global distribution network covering approximately 65 countries. The deal is expected to close in the next few months and is subject to customary closing conditions.
Editor
Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.